UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Eight-week treatment with sofosbuvir/velpatasvir may be effective in curing hepatitis C in children

Pediatria polska, 2024-09, Vol.99 (3), p.266-269

2024

Volltextzugriff (PDF)

Development of Reverse Phase HPLC Method and Validation: Sofosbuvir and Velpatasvir Quantification in Bulk and Tablets

INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE, 2023-12, Vol.14 (4), p.831-836

2023

Volltextzugriff (PDF)

Collocation of Buprenorphine with HCV treatment to improve adherence and reduce harm in PWID with HCV: Preliminary data from the ANCHOR study

Journal of hepatology, 2018, Vol.68, p.S51

2018

Volltextzugriff (PDF)

索磷布韦/维帕他韦单用或联合利巴韦林治疗3B型HCV/HIV感染者的效果及安全性

临床肝胆病杂志, 2024-02, Vol.40 (2), p.271-277

2024

Volltextzugriff (PDF)

An environmentally sustainable synchronous spectrofluorimetric method coupled with second derivative signal processing for simultaneous determination of velpatasvir and simeprevir in pharmaceutical and plasma samples

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2025-02, Vol.326, p.125202, Article 125202

2025

Volltextzugriff (PDF)

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 2; peer review: 3 approved]

F1000 research, 2020, Vol.9, p.129

2020

Volltextzugriff (PDF)

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection

Journal of hepatology, 2018-11, Vol.69 (5), p.1178-1187

2018

Volltextzugriff (PDF)

Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy

Journal of gastrointestinal and liver diseases : JGLD, 2022-12, Vol.31 (4), p.437-443

2022

Volltextzugriff (PDF)

EFFECTIVENESS AND SAFETY OF SOFOSBUVIR AND VELPATASVIR IN HEMODIALYSIS PATIENTS SUFFERING WITH HEPATITIS C INFECTION

Journal of University Medical & Dental College, 2021-02, Vol.12 (1), p.24-29

2021

Volltextzugriff (PDF)

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application

Journal of education, health and sport, 2023-02, Vol.13 (3), p.200-206

2023

Volltextzugriff (PDF)

Electrochemical Sensor Modified with Graphene Oxide Decorated with Copper Oxide Nanoparticles for Velpatasvir’s Monitoring in Spiked Human Plasma

Journal of the Electrochemical Society, 2024-05, Vol.171 (5), p.57511

2024

Volltextzugriff (PDF)

A dispersive liquid–liquid microextraction method based on solidification of floating organic droplet for determination of antiviral agents in environmental water using HPLC/UV

Microchemical journal, 2021-12, Vol.171, p.106790, Article 106790

2021

Volltextzugriff (PDF)

Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study

Liver international, 2023-09, Vol.43 (9), p.1871-1878

2023

Volltextzugriff (PDF)

Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection

Journal of hepatology, 2022-10, Vol.77 (4), p.1215-1217

2022

Volltextzugriff (PDF)

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers

Clinical infectious diseases, 2018-08, Vol.67 (6), p.934-940

2018

Volltextzugriff (PDF)

Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed

Internal Medicine, 2021, pp.7028-21

2021

Volltextzugriff (PDF)

Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs

Journal of hepatology, 2023-09, Vol.79 (3), p.e121-e123

2023

Volltextzugriff (PDF)

Green RP-HPLC method for simultaneous determination of sofosbuvir, ledipasvir, velpatasvir antivirals and beyond in their bulk material and co-formulated products

Microchemical journal, 2023-03, Vol.186, p.108344, Article 108344

2023

Volltextzugriff (PDF)

Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry

Clinical infectious diseases, 2021-06, Vol.72 (11), p.e799-e805

2021

Volltextzugriff (PDF)

Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes

Journal of hepatology, 2018, Vol.68, p.S256-S257

2018

Volltextzugriff (PDF)

Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?

Hepatology research, 2022-10, Vol.52 (10), p.815-816

Toyoda, Hidenori

2022

Volltextzugriff (PDF)

Hepatitis C virus therapy: No one will be left behind

International journal of antimicrobial agents, 2019-06, Vol.53 (6), p.755-760

2019

Volltextzugriff (PDF)

Novel determination of a new antiviral combination; sofosbuvir and velpatasvir by high performance thin layer chromatographic method; application to real human samples

Microchemical journal, 2019-05, Vol.146, p.828-834

2019

Volltextzugriff (PDF)

Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis

Medicine (Baltimore), 2022-10, Vol.101 (42), p.e31183-e31183

2022

Volltextzugriff (PDF)

1 – 25 von 240

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(204)
Mit Volltextzugriff
(205)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(182)
Velpatasvir
(166)
Life Sciences & Biomedicine
(160)
Sofosbuvir
(155)
Hepatitis C
(114)
Humans
(81)
Hepatitis C Virus
(76)
Gastroenterology & Hepatology
(64)
Hepatitis
(52)
Antiviral Drugs
(50)
Hepatitis C, Chronic - Drug Therapy
(48)
Liver Cirrhosis
(48)
Antiviral Agents - Therapeutic Use
(45)
Antiviral Agents
(44)
Patients
(44)
Genotype
(43)
Sofosbuvir - Therapeutic Use
(41)
Sofosbuvir/velpatasvir
(40)
Infectious Diseases
(39)
Pharmacology & Pharmacy
(39)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Eight-week treatment with sofosbuvir/velpatasvir may be effective in curing hepatitis C in children

Development of Reverse Phase HPLC Method and Validation: Sofosbuvir and Velpatasvir Quantification in Bulk and Tablets

Collocation of Buprenorphine with HCV treatment to improve adherence and reduce harm in PWID with HCV: Preliminary data from the ANCHOR study

索磷布韦/维帕他韦单用或联合利巴韦林治疗3B型HCV/HIV感染者的效果及安全性

An environmentally sustainable synchronous spectrofluorimetric method coupled with second derivative signal processing for simultaneous determination of velpatasvir and simeprevir in pharmaceutical and plasma samples

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 2; peer review: 3 approved]

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection

Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics

Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy

EFFECTIVENESS AND SAFETY OF SOFOSBUVIR AND VELPATASVIR IN HEMODIALYSIS PATIENTS SUFFERING WITH HEPATITIS C INFECTION

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application

Electrochemical Sensor Modified with Graphene Oxide Decorated with Copper Oxide Nanoparticles for Velpatasvir’s Monitoring in Spiked Human Plasma

A dispersive liquid–liquid microextraction method based on solidification of floating organic droplet for determination of antiviral agents in environmental water using HPLC/UV

Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study

Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers

Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed

Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs

Green RP-HPLC method for simultaneous determination of sofosbuvir, ledipasvir, velpatasvir antivirals and beyond in their bulk material and co-formulated products

Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry

Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes

Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?

Hepatitis C virus therapy: No one will be left behind

Novel determination of a new antiviral combination; sofosbuvir and velpatasvir by high performance thin layer chromatographic method; application to real human samples

Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis

Suchergebnisse filtern